Seat­tle Ge­net­ics seeds a new im­muno-on­col­o­gy col­lab­o­ra­tion with the pro­tein ex­plor­ers at Pieris

Seat­tle Ge­net­ics $SGEN be­lieves it could achieve some block­buster can­cer drug work by team­ing up with the pro­tein en­gi­neers at Pieris $PIRS.

The Seat­tle-based biotech is seed­ing a joint dis­cov­ery ef­fort that match­es its suc­cess­ful work on an­ti­body drug con­ju­gates with Pieris’s An­ti­calin plat­form, get­ting the work start­ed with a $30 mil­lion pay­ment.

Should it all work out ac­cord­ing to plan — al­ways a long shot in biotech — Pieris can earn up to $1.2 bil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.